Literature DB >> 28254678

Incidence of Occult Uterine Malignancy Following Vaginal Hysterectomy With Morcellation.

Megan Wasson1, Paul Magtibay2, Paul Magtibay2, Javier Magrina2.   

Abstract

STUDY
OBJECTIVE: To determine the incidence and impact of occult uterine malignancy following vaginal hysterectomy and uncontained morcellation.
DESIGN: An Institutional Review Board-approved retrospective cohort study (Canadian Task Force classification II-2).
SETTING: Three academic medical centers. PATIENTS: All women who underwent vaginal hysterectomy between January 1, 2008, and August 31, 2015, at 3 institutions were considered for inclusion in the study.
INTERVENTIONS: Total vaginal hysterectomy with and without morcellation.
MEASUREMENTS AND MAIN RESULTS: A total of 2296 women underwent total vaginal hysterectomy without (n = 1685) or with (n = 611) vaginal morcellation performed via cold-knife wedge resection. All patients requiring morcellation had benign indications for hysterectomy. The incidence of occult uterine malignancy among hysterectomies requiring vaginal morcellation was 0.82% (n = 5) and included stage IA, grade I endometrial adenocarcinoma (n = 3; 0.49%) and low grade stromal sarcoma (n = 2; 0.33%). Demographic data for those with occult malignancy included mean age 48.8 years, mean body mass index 32.36 kg/m2, and median parity 2. Indication for hysterectomy was abnormal uterine bleeding for the 5 patients who underwent morcellation and were found to have a malignancy. Final pathology revealed a mean uterine weight of 231.60 g. All patients have remained disease-free, and no deaths have occurred. Mean disease-free survival was 48.33 months (range, 33-67 months) for the patients with endometrial adenocarcinoma and 42.0 months (range, 19-65 months) for the patients with stromal sarcoma for the 5 patients who underwent vaginal hysterectomy with morcellation.
CONCLUSION: Among patients undergoing vaginal hysterectomy with morcellation, the incidence of occult uterine carcinoma is 0.82%. Uncontained vaginal morcellation when used concomitantly with vaginal hysterectomy does not appear to negatively impact patient prognosis or outcomes.
Copyright © 2017 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Uterus; cancer; morcellate

Mesh:

Year:  2017        PMID: 28254678     DOI: 10.1016/j.jmig.2017.01.025

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  4 in total

1.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

2.  Comparison of Robotic and Laparoscopic Hysterectomy for the Large Uterus.

Authors:  Rooma Sinha; Rupa Bana; Madhumathi Sanjay
Journal:  JSLS       Date:  2019 Jan-Mar       Impact factor: 2.172

3.  Current Methods of Tissue Extraction in Minimally Invasive Surgical Treatment of Uterine Fibroids.

Authors:  Renita Kim; Kristen Pepin; Monalisa Dmello; Nisse Clark; Mobolaji Ajao; Jon Einarsson; Sarah Cohen Rassier
Journal:  JSLS       Date:  2022 Jul-Sep       Impact factor: 1.789

4.  Risk Factors Associated with Perineal and Vaginal Lacerations and Vaginal Removal in Total Laparoscopic Hysterectomy.

Authors:  Kenro Chikazawa; Ken Imai; Hiroyoshi Ko; Naoki Ichi; Masahiro Misawa; Tomoyuki Kuwata
Journal:  Gynecol Minim Invasive Ther       Date:  2022-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.